



Newsletter, 2020-04-24

RhoVac featured in international trade press

RhoVac AB ("RhoVac") was featured in the international trade press, April 24, as the well reputed industry-specific e-journal Scrip - Pharma Intelligence published an interview with CEO Anders Månsson.

The well reputed industry-specific e-journal Scrip - Pharma Intelligence, interviewed CEO Anders Månsson about the company's ongoing clinical phase IIb study in prostate cancer, called BRaVac. In the interview, CEO Anders Månsson explains that RhoVac's RV001 treatment is "tissue agnostic", i.e. that the treatment is not limited to prostate cancer only, but that it could probably be developed for several different metastatic cancer indications. The article further describes the randomized, placebo-controlled and double-blinded multicenter study in prostate cancer, which will recruit over 175 patients in the United States and in six European countries (Denmark, Finland, Belgium, Sweden and the United Kingdom), where Germany was the latest country to start treatment of patients, April 23. "Overall, we have funding that is expected to meet the company's needs until the second half of 2022, which we believe is sufficient to complete the phase IIb study and reach a possible exit," commented Anders Månsson in *Scrip*.

For more information, please contact:

Anders Månsson – CEO, RhoVac AB

Phone: +46 73-751 72 78

E-mail: info@rhovac.com

About RhoVac AB

RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is immediately launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com